Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Final results from 18 years of the International Lamotrigine Pregnancy Registry.

Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P.

Neurology. 2011 May 24;76(21):1817-23. doi: 10.1212/WNL.0b013e31821ccd18.

PMID:
21606453
2.

Preliminary results on pregnancy outcomes in women using lamotrigine.

Tennis P, Eldridge RR; International Lamotrigine Pregnancy Registry Scientific Advisory Committee.

Epilepsia. 2002 Oct;43(10):1161-7.

3.

Lamotrigine and the risk of malformations in pregnancy.

Cunnington M, Tennis P; International Lamotrigine Pregnancy Registry Scientific Advisory Committee.

Neurology. 2005 Mar 22;64(6):955-60.

PMID:
15781807
4.

Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.

Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, Liggan B, Irwin B, Delanty N, Hunt SJ, Craig J, Morrow J.

J Neurol Neurosurg Psychiatry. 2014 Sep;85(9):1029-34. doi: 10.1136/jnnp-2013-306318. Epub 2014 Jan 20.

PMID:
24444855
5.

Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F; EURAP study group.

Lancet Neurol. 2011 Jul;10(7):609-17. doi: 10.1016/S1474-4422(11)70107-7. Epub 2011 Jun 5.

PMID:
21652013
6.

Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.

Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S.

Arch Neurol. 2011 Oct;68(10):1275-81. doi: 10.1001/archneurol.2011.133. Epub 2011 Jun 13.

PMID:
21670385
7.

The teratogenic risk of antiepileptic drug polytherapy.

Vajda FJ, Hitchcock AA, Graham J, O'Brien TJ, Lander CM, Eadie MJ.

Epilepsia. 2010 May;51(5):805-10. doi: 10.1111/j.1528-1167.2009.02336.x. Epub 2009 Oct 8. Review.

8.

Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F; EURAP Study Group.

Neurology. 2015 Sep 8;85(10):866-72. doi: 10.1212/WNL.0000000000001772. Epub 2015 Jun 17.

PMID:
26085607
9.
10.

Valproic acid monotherapy in pregnancy and major congenital malformations.

Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, de Jong-van den Berg LT; EUROCAT Antiepileptic Study Working Group.

N Engl J Med. 2010 Jun 10;362(23):2185-93. doi: 10.1056/NEJMoa0907328. Review.

11.

The teratogenicity of the newer antiepileptic drugs - an update.

Vajda FJ, O'Brien TJ, Lander CM, Graham J, Eadie MJ.

Acta Neurol Scand. 2014 Oct;130(4):234-8. doi: 10.1111/ane.12280. Epub 2014 Jul 18.

PMID:
25040242
12.

Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.

Cunnington M, Ferber S, Quartey G; International Lamotrigine Pregnancy Registry Scientific Advisory Committee.

Epilepsia. 2007 Jun;48(6):1207-10. Epub 2007 Mar 22.

13.

Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.

Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB.

Am J Obstet Gynecol. 2000 Jan;182(1 Pt 1):159-63.

PMID:
10649172
14.

Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.

Ephross SA, Sinclair SM.

Headache. 2014 Jul-Aug;54(7):1158-72. doi: 10.1111/head.12375. Epub 2014 May 7.

PMID:
24805878
15.

[Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years].

Martínez Ferri M, Peña Mayor P, Pérez López-Fraile I, Castro Vilanova MD, Escartín Siquier A, Martín Moro M, Forcadas Berdusan M; registro EURAP España.

Neurologia. 2009 Jul-Aug;24(6):360-5. Spanish.

PMID:
19798601
16.

Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India.

Thomas SV, Jose M, Divakaran S, Sankara Sarma P.

Epilepsia. 2017 Feb;58(2):274-281. doi: 10.1111/epi.13632. Epub 2017 Jan 13.

PMID:
28084641
17.

Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies.

Dolk H, Wang H, Loane M, Morris J, Garne E, Addor MC, Arriola L, Bakker M, Barisic I, Doray B, Gatt M, Kallen K, Khoshnood B, Klungsoyr K, Lahesmaa-Korpinen AM, Latos-Bielenska A, Mejnartowicz JP, Nelen V, Neville A, O'Mahony M, Pierini A, Rißmann A, Tucker D, Wellesley D, Wiesel A, de Jong-van den Berg LT.

Neurology. 2016 May 3;86(18):1716-25. doi: 10.1212/WNL.0000000000002540. Epub 2016 Apr 6.

18.

Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.

Tomson T, Perucca E, Battino D.

Epilepsia. 2004 Oct;45(10):1171-5.

19.

Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C; American Academy of Neurology; American Epilepsy Society.

Epilepsia. 2009 May;50(5):1237-46. Review.

PMID:
19507301
20.

Newer anticonvulsants: lamotrigine, topiramate and gabapentin.

Holmes LB, Hernandez-Diaz S.

Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):599-606. doi: 10.1002/bdra.23028. Epub 2012 Jun 22.

PMID:
22730257

Supplemental Content

Support Center